Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma, Experimental | 4 | 2022 | 368 | 1.990 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2022 | 1586 | 0.960 |
Why?
|
| Interleukin-1alpha | 1 | 2021 | 56 | 0.770 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2022 | 33 | 0.710 |
Why?
|
| CD40 Ligand | 1 | 2017 | 115 | 0.600 |
Why?
|
| CD40 Antigens | 1 | 2017 | 104 | 0.590 |
Why?
|
| Immunotherapy, Active | 1 | 2015 | 46 | 0.520 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 21 | 0.510 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2010 | 1033 | 0.480 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 149 | 0.460 |
Why?
|
| Immunotherapy | 3 | 2022 | 3341 | 0.440 |
Why?
|
| Melanoma | 4 | 2020 | 5317 | 0.410 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2020 | 673 | 0.400 |
Why?
|
| Rhinovirus | 1 | 2010 | 94 | 0.370 |
Why?
|
| Immunity, Innate | 1 | 2014 | 677 | 0.370 |
Why?
|
| Picornaviridae Infections | 1 | 2010 | 57 | 0.360 |
Why?
|
| Cysteine Endopeptidases | 1 | 2010 | 251 | 0.340 |
Why?
|
| Cytokines | 3 | 2021 | 2809 | 0.340 |
Why?
|
| CTLA-4 Antigen | 3 | 2018 | 657 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 5 | 2022 | 6942 | 0.320 |
Why?
|
| Viral Proteins | 1 | 2010 | 435 | 0.300 |
Why?
|
| CD28 Antigens | 1 | 2008 | 202 | 0.300 |
Why?
|
| Cancer Vaccines | 3 | 2018 | 697 | 0.300 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5178 | 0.290 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2015 | 1763 | 0.260 |
Why?
|
| Lymphocyte Activation | 4 | 2020 | 1688 | 0.240 |
Why?
|
| Mice | 9 | 2022 | 34495 | 0.210 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 1021 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2864 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4849 | 0.190 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 100 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 4367 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 14551 | 0.180 |
Why?
|
| Dendritic Cells | 3 | 2018 | 1085 | 0.170 |
Why?
|
| Antibodies | 1 | 2022 | 838 | 0.170 |
Why?
|
| Animals | 9 | 2022 | 59536 | 0.160 |
Why?
|
| Interferon-gamma | 3 | 2020 | 1144 | 0.160 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.160 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2018 | 88 | 0.160 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 58 | 0.160 |
Why?
|
| Chemokine CCL2 | 2 | 2018 | 203 | 0.150 |
Why?
|
| Neutrophils | 1 | 2021 | 835 | 0.140 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 278 | 0.140 |
Why?
|
| Interleukin-2 | 1 | 2020 | 842 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 615 | 0.140 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 203 | 0.140 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 164 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 750 | 0.120 |
Why?
|
| Enzyme Activation | 1 | 2017 | 1764 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 3869 | 0.120 |
Why?
|
| Oncolytic Viruses | 1 | 2015 | 204 | 0.110 |
Why?
|
| Microbial Viability | 1 | 2012 | 62 | 0.110 |
Why?
|
| Klebsiella Infections | 1 | 2012 | 64 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 675 | 0.110 |
Why?
|
| Leukocytes | 1 | 2014 | 422 | 0.110 |
Why?
|
| Klebsiella pneumoniae | 1 | 2012 | 98 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2017 | 1459 | 0.100 |
Why?
|
| Peptides | 1 | 2018 | 1479 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 6207 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1022 | 0.100 |
Why?
|
| beta-Lactamases | 1 | 2012 | 179 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 2014 | 644 | 0.090 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2010 | 53 | 0.090 |
Why?
|
| Interleukin-4 | 1 | 2010 | 284 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 254 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 992 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2010 | 257 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2010 | 250 | 0.080 |
Why?
|
| Imidazoles | 1 | 2014 | 999 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2014 | 1987 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 1506 | 0.080 |
Why?
|
| Interleukin-7 | 1 | 2008 | 95 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2008 | 99 | 0.080 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 66 | 0.080 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 105 | 0.080 |
Why?
|
| Leukocyte Common Antigens | 1 | 2008 | 188 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2017 | 5710 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2021 | 11965 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2326 | 0.080 |
Why?
|
| Androstadienes | 1 | 2008 | 165 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 1029 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2008 | 626 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 709 | 0.060 |
Why?
|
| Humans | 8 | 2022 | 261506 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 582 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2010 | 5637 | 0.060 |
Why?
|
| Brain | 1 | 2017 | 4113 | 0.060 |
Why?
|
| Pneumonia | 1 | 2010 | 751 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 778 | 0.060 |
Why?
|
| Phenotype | 1 | 2014 | 6295 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2008 | 548 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 2315 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 1879 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 2992 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2020 | 186 | 0.040 |
Why?
|
| Receptors, CXCR3 | 1 | 2018 | 36 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 221 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2008 | 4078 | 0.040 |
Why?
|
| Female | 4 | 2020 | 141928 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2008 | 7226 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2020 | 710 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 14889 | 0.030 |
Why?
|
| Adult | 3 | 2010 | 77950 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Monocytes | 1 | 2018 | 788 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2012 | 46 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 130 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4143 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 994 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2008 | 354 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 1489 | 0.020 |
Why?
|
| Aged | 1 | 2010 | 70117 | 0.020 |
Why?
|
| Middle Aged | 1 | 2010 | 86204 | 0.010 |
Why?
|
| Lung | 1 | 2012 | 3151 | 0.010 |
Why?
|
| Male | 1 | 2010 | 123000 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 4971 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 7222 | 0.010 |
Why?
|
| Neoplasms | 1 | 2018 | 15193 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 32848 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 31252 | 0.000 |
Why?
|